Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background The role of renin-angiotensin inhibition in older systolic heart failure patients with chronic kidney disease remains unclear. Methods Of the 1665 patients, age ≥65 years, with systolic heart failure (ejection fraction <45%) and chronic kidney disease (estimated glomerular filtration rate <60 ml/min/1.73 m2), 1046 received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Propensity scores for the receipts of these drugs, estimated for each of the 1665 patients, were used to assemble a matched cohort of 444 pairs of patients receiving and not receiving these drugs who were balanced on 56 baseline characteristics. Results During over 8 years of follow-up, all-cause mortality occurred in 75% and 79% of matched patients with chronic kidney disease receiving and not receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, respectively (hazard ratio {HR}, 0.86; 95% confidence interval {CI}, 0.74–0.996; p=0.045). There was no significant association with heart failure hospitalization (HR, 0.86; 95% CI, 0.72–1.03; p=0.094). Similar mortality reduction (HR, 0.83; 95% CI, 0.70–1.00; p=0.046) occurred in a subgroup of matched patients with estimated glomerular filtration rate <45 ml/min/1.73 m2. Among 171 pairs of propensity-matched patients without chronic kidney disease, the use of these drugs was associated with significant reduction in all-cause mortality (HR, 0.72; 95% CI, 0.55–0.94; p=0.015) and heart failure hospitalization (HR, 0.71; 95% CI, 0.52–0.95; p=0.023). Conclusions Discharge prescription of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a significant modest reduction in all-cause mortality in older systolic heart failure patients with chronic kidney disease including those with more advanced chronic kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation
Rubin, D. B. (2001) · Health Services and Outcomes Research Methodology · doi:10.1023/a:1020363010465 · Cited by 2,228 · cited 2×
“Calcium channel blockers 37 (17) 1 Potassium supplements 96 (45) 3 Nitrates and hydralazine 4 (2) Antiarrhythmic drugs 34 (16) Anticoagulants 60 (28) 2 Antiplatelet drugs 18 (8) Aspirin 64 (30) 3 Insulin 15 (7) Statins 24 (11) 1 Antidepressants 44 (21) 1 Nonsteroidal anti-inflammatory drugs 21 (10)”
Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation · doi:10.1161/01.cir.100.23.2312 · Cited by 1,244
Subgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823 · cited 3×
“810 Acute myocardial infarction 17 (8) 33 (5) .”
Self-citationEfficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710 · cited 4×
“Potassium-sparing diuretics 87 (14) 21 Digoxin 275 (44) 62 Calcium channel blockers 126 (20) 16 Potassium supplements 240 (39) 47 Nitrates and hydralazine 95 (15) Antiarrhythmic drugs 130 (21) 18 Anticoagulants 150 (24) 30 Antiplatelet drugs 64 (10) 12 Aspirin 223 (36) 48 Insulin 94 (15) 15 Statins 86 (14) 18 Antidepr…”
InfluentialAn overview of the objectives of and the approaches to propensity score analyses
Heinze, G., & Jüni, P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr031 · Cited by 379
Cited by
Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,409
Mullens, W., Damman, K., Testani, J. M., Martens, P., Mueller, C., Lassus, J., Tang, W. H. W., Skouri, H., Verbrugge, F. H., Orso, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1697 · Cited by 411
Bernstein, K. E., Ong, F. S., Blackwell, W.-L. B., Shah, K. H., Giani, J. F., Gonzalez-Villalobos, R. A., Shen, X. Z., & Fuchs, S. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006809 · Cited by 324
Gheorghiade, M., Fonarow, G. C., van Veldhuisen, D. J., Cleland, J. G. F., Butler, J., Epstein, A. E., Patel, K., Aban, I. B., Aronow, W. S., Anker, S. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht120 · Cited by 192
Self-citationBowling, C. B., Sanders, P. W., Allman, R. M., Rogers, W. J., Patel, K., Aban, I. B., Rich, M. W., Pitt, B., White, M., Bakris, G. C., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.056 · Cited by 85
“These findings are also consistent with those from a propensity-matched study of ACEIs in SHF patients with CKD [25].”
ResultSelf-citation
Metadata
- Authors
- Ahmed, A., Fonarow, G. C., Zhang, Y., Sanders, P. W., Allman, R. M., Arnett, D. K., Feller, M. A., Love, T. E., Aban, I. B., Levesque, R., Ekundayo, O. J., Dell'Italia, L. J., Bakris, G. L., & Rich, M. W.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 125
- Issue
- 4
- Pages
- 399-410
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2043560686
- Cited by
- 78
- References
- 6
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.